1/12
07:39 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
1/12
07:39 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
1/12
07:17 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Sanford C. Bernstein to an "outperform" rating.
1/12
05:53 am
vrtx
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
Low
Report
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
1/12
05:53 am
vrtx
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
Low
Report
Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
1/7
08:40 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
1/6
08:20 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $548.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $548.00 price target on the stock.
1/6
08:20 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $548.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $548.00 price target on the stock.
1/6
08:15 am
vrtx
Rating for VRTX
Medium
Report
Rating for VRTX
1/6
08:15 am
vrtx
Rating for VRTX
Medium
Report
Rating for VRTX
1/6
07:44 am
vrtx
Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research
Medium
Report
Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research
1/6
07:44 am
vrtx
Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research
Medium
Report
Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research
12/29
08:56 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/10
03:07 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/10
03:07 pm
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/9
08:11 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
12/5
10:30 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/5
10:30 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/3
10:33 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/3
10:33 am
vrtx
Rating for VRTX
Low
Report
Rating for VRTX
12/3
08:44 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
12/3
08:44 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
Medium
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $516.00 price target on the stock.
12/3
05:06 am
vrtx
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
Medium
Report
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
12/3
05:06 am
vrtx
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
Medium
Report
Vertex upgraded to Overweight from Equal Weight at Morgan Stanley
11/14
07:54 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at Scotiabank to a "strong-buy" rating.